In Vivo Podcasts
de Norstella
Strategic Intent: Praxis CEO On Unlearning, AI And Launching Two…
À propos de ce podcast
In Vivo Podcasts is produced by the teams behind In Vivo, Scrip and Medtech Insight and covers biopharma and medtech in one place: the strategy, the science and the deals.
Every Tuesday, Strategic Intent is a candid, long-form conversation with one senior guest, including chief executives, R&D leaders, investors and regulators. Once a month, Proof of Concept goes deep on the science, from AI-designed drug discovery to the RNA therapeutics wave. And each month Scrip's Due Diligence follows the money: the M&A, licensing and financings redrawing the industry. Hosted by a rotating line-up of editors and reporters. Stay ahead with expert insight and intelligence.
Visit https://insights.citeline.com/in-vivo for daily newsletters and life sciences commercial intelligence. For any podcast feedback or queries, you can now reach us at [email protected].
Épisodes
Les 20 épisodes les plus récents sur 33
- Strategic Intent: Praxis CEO On Unlearning, AI And Launching Two Neuroscience Drugs At Once · 45 minPraxis Precision Medicines is within weeks of FDA decisions on two potential firsts: relutrigine for SCN2A and SCN8A developmental and epileptic encephalopathies, and…
- Special Episode: Topspin and Why Product Demand, Not Coverage, Drives Formulary Power · 49 minConventional wisdom says you secure coverage first, then build demand. What if the causality runs the other way? In this special In Vivo podcast episode, senior reporter David…
- Strategic Intent: Lundbeck On Reimbursement, Risk And The Return Of Neuroscience · 20 minIn this episode of Strategic Intent, Maria Alfaiate, Executive Vice President for Corporate Portfolio and Product Strategy at Lundbeck, discusses neuroscience's growing…
- Proof of Concept: The Money Is Back In RNA, But What Stands Between Headlines And Routine Medicine? · 40 min"The money is back in RNA. In recent weeks, Merck KGaA agreed to pay about $1.1 billion for Silence Therapeutics, Novartis signed a deal worth up to $7.8 billion with Abogen…
- Strategic Intent: How Circio Rebuilt Itself Around Circular RNA · 49 minMost biotech companies spend their time creating value. Far fewer have to figure out how to rebuild it. Erik Wiklund, CEO of Norwegian biotech Circio, has done both. Three and a…
- Strategic Intent: Understanding Crossover Strategies in Biotech With Sofinnova Partners’ David Evans · 30 minIn this episode of Strategic Intent, Partner at Sofinnova Partners, David Evans discusses his transition from Roche Venture Fund, different investments strategies, general market…
- Strategic Intent: Can Blood Tests Break the Alzheimer’s Diagnosis Bottleneck? · 29 minDisease-modifying Alzheimer’s treatments have arrived, but diagnosing the right patients at scale is still a major bottleneck. In this episode of Strategic Intent, Marion Webb…
- Strategic Intent: Celebrity Marketing In The Age Of Promo Crackdown · 27 minCan a celebrity campaign still work for a drug company when the FDA is watching every word? In this episode of Strategic Intent, Frank Watanabe, CEO of Arcutis Biotherapeutics…
- Strategic Intent: Using Agentic AI To Create ‘The Self-Driving Clinical Trial, Kind Of Like The Car’ · 33 minIn this Strategic Intent episode, In Vivo speaks with Ken Getz, executive director of the Tufts CSDD and research professor at the Tufts University School of Medicine, and Pamela…
- Proof of Concept - Can AI Outrun the Next Outbreak? · 40 minWhat if you could design a diagnostic and a therapeutic directly from a pathogen's genetic code, faster than the disease can spread? Jared Bauer, co-founder and CEO of Seek Labs…
- Assessing the current dealmaking environment for psychedelic medicine. · 20 minJoseph Haas and Emma Wille overview the dealmaking environment for psychedelic medicine given recent developments in the space: Eli Lilly's $2.8 billion acquisition of…
- Strategic Intent: Boehringer Ingelheim's Brian Hilberdink on Launching Into the GLP-1 Era · 30 minBrian Hilberdink, President of US Human Pharma at Boehringer Ingelheim, joined Strategic Intent to talk about leading one of the company's most ambitious US launch periods in…
- Strategic Intent: Rubedo’s Seno-Adaptive Bet On Longevity Medicine · 40 minIn this episode of Strategic Intent, In Vivo senior reporter David Wild speaks with Frederick Beddingfield, CEO of Rubedo Life Sciences, about turning the biology of aging into…
- Strategic Intent: Next‑Generation Cancer Vaccines And Nouscom’s Strategy For Interception And Personalization · 36 minPersonalized and off‑the‑shelf cancer vaccines are moving from concept to clinic, raising new questions about differentiation, manufacturability, and commercial value. In this…
- Strategic Intent: Evolving Requirements Of Life Sciences Leadership · 21 minIn this episode of Strategic Intent, Nick Stephens, chairman of the recruitment and executive placement company RSA group, looks at the state of executive leadership across the…
- Proof Of Concept: How A Charity Bridges Lab And Clinic · 21 minCancer Research UK is best known for funding science. But its commercial arm, Cancer Research Horizons, does something less obvious: it builds companies. This episode features…
- Strategic Intent: Beyond The Breakthrough - From Approval To Adoption · 40 minA medical device can work beautifully and still go nowhere. In this episode of Strategic Intent, Krishna Eluri sits down with Mark Saxton, U.S. CEO of Baird Medical, who has…
- ZS On How AI is Reshaping The Patient's Approach to Care Delivery - a View From the US, China and Germany · 36 minA landmark three-country survey by the ZS consulting and technology firm , which shows the rapid trend towards patients' uptake of AI tools that empower them on their healthcare…
- Videocast: Goodwin’s Sophie McGrath – A Legal View Of Healthtech And Biopharma Trends · 41 minA videocast for the In Vivo podcast section, with Goodwin's Sophie McGrath - talking about healthtech and pharma trends. Innovation, investment, legal, Goodwin, Sophie McGrath…
- Bonus Episode: Inside Endocyclic’s Precision Peptide Strategy For Endometriosis Diagnosis And Treatment · 33 minOne in ten women has endometriosis, yet treatment options remain largely unchanged for decades. Tanya Petrossian, CEO of EndoCyclic Therapeutics, explains how her company's…








